Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Trial of SHR1258 in Patients With Biliary Tract Cancer
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT04571710
The PK/PD Study of SHR7280 Tablets in Healthy Subjects.
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT04554043
- Locations
- 🇨🇳
Affiliated Hospital of Qingdao University, Qingdao, Shan Dong, China
A Trial of HR18034 in Inguinal Hernia Repair
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT04551924
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT04527484
Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04521192
- Locations
- 🇨🇳
The affiliated hospital of QingDao university, Qingdao, Qingdao, China
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 142
- Registration Number
- NCT04517357
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 101
- Registration Number
- NCT04513223
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on Famitinib
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT04494659
- Locations
- 🇨🇳
Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 504
- Registration Number
- NCT04481139
- Locations
- 🇨🇳
Zhanguo Li, Beijing, Beijing, China
A Trial of SHR-1703 in Healthy Adults
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04480762
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
© Copyright 2024. All Rights Reserved by MedPath